CoChat
Sign Up
Cited by 127

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Mesenchymal stem cell-derived exosome: A tumor regulator and carrier for targeted tumor therapy

Zhang, Fusheng, Guo, Jinshuai, Zhang, Zhenghou, Qian, Yiping, Wang, Guang, Duan, Meiqi, Zhao, Haiying, Yang, Zhi, Jiang, Xiaofeng·2022·Cancer Letters
DOI 10.1016/j.canlet.2021.11.015
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.canlet.2021.11.015

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY-NC-ND · From the PDF
Fig. 1 The influence of exosomes on tumor progression. MSCs-Exo influence tumor progression through different pathways. Promoting tumors: A: including the regulation of the secretion of mediators of angiogenesis; B: promoting immune escape by regulating macrophage polarization and inhibiting T-cell activation; C: stimulates tumor cell proliferation by affecting signaling pathways; D: the tumor microenvironment mediates cancer-associated fibroblast (CAF) formation by educating MSCs-Exo; E: MSCs-Exo increase drug resistance. Inhibiting tumors: a: inhibition of angiogenesis; b: inhibition of tumor proliferation through miRNAmediated signaling pathways; c: increase the number and sensitivity of T cells and NK cells; d: improving drug sensitivity.
Fig. 1 The influence of exosomes on tumor progression. MSCs-Exo influence tumor progression through different pathways. Promoting tumors: A: including the regulation of the secretion of mediators of angiogenesis; B: promoting immune escape by regulating macrophage polarization and inhibiting T-cell activation; C: stimulates tumor cell proliferation by affecting signaling pathways; D: the tumor microenvironment mediates cancer-associated fibroblast (CAF) formation by educating MSCs-Exo; E: MSCs-Exo increase drug resistance. Inhibiting tumors: a: inhibition of angiogenesis; b: inhibition of tumor proliferation through miRNAmediated signaling pathways; c: increase the number and sensitivity of T cells and NK cells; d: improving drug sensitivity.CC-BY-NC-ND · From the PDF
Fig. 2 Drug delivery system of MSCs-Exo for tumor therapy. A: Vascular system leakage leads to passive accumulation of MSCs-Exo at the tumor. B: As drug carriers, MSCs-Exo are loaded with a variety of antitumor drugs for tumor treatment. C: Using certain tumor-targeting substances to improve the efficiency of MSCs-Exo targeted tumor therapy.
Fig. 2 Drug delivery system of MSCs-Exo for tumor therapy. A: Vascular system leakage leads to passive accumulation of MSCs-Exo at the tumor. B: As drug carriers, MSCs-Exo are loaded with a variety of antitumor drugs for tumor treatment. C: Using certain tumor-targeting substances to improve the efficiency of MSCs-Exo targeted tumor therapy.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 131

  1. Siegel, 2020, Cancer statistics, 2020, CA A Cancer J. Clin., 70, 7
  2. Scadden, 2006, The stem-cell niche as an entity of action, Nature, 441, 1075, 10.1038/nature04957 · DOI
  3. Bianco, 2008, Mesenchymal stem cells: revisiting history, concepts, and assays, Cell Stem Cell, 2, 313, 10.1016/j.stem.2008.03.002 · DOI
  4. Squillaro, 2016, Clinical trials with mesenchymal stem cells: an update, Cell Transplant., 25, 829, 10.3727/096368915X689622 · DOI
  5. Galipeau, 2018, Mesenchymal stromal cells: clinical challenges and therapeutic opportunities, Cell Stem Cell, 22, 824, 10.1016/j.stem.2018.05.004 · DOI · Paper page
  6. Whiteside, 2018, Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment, Semin. Immunol., 35, 69, 10.1016/j.smim.2017.12.003 · DOI
  7. Hidalgo-Garcia, 2018, Can a conversation between mesenchymal stromal cells and macrophages solve the crisis in the inflamed intestine?, Front. Pharmacol., 9, 179, 10.3389/fphar.2018.00179 · DOI
  8. Ridge, 2017, Mesenchymal stem cells: key players in cancer progression, Mol. Cancer, 16, 31, 10.1186/s12943-017-0597-8 · DOI
  9. Devarasetty, 2017, Mesenchymal stem cells support growth and organization of host-liver colorectal-tumor organoids and possibly resistance to chemotherapy, Biofabrication, 9, 10.1088/1758-5090/aa7484 · DOI
  10. Sierra-Parraga, 2020, Reparative effect of mesenchymal stromal cells on endothelial cells after hypoxic and inflammatory injury, Stem Cell Res. Ther., 11, 352, 10.1186/s13287-020-01869-3 · DOI
  11. Rangel, 2018, Kidney-derived c-kit(+) progenitor/stem cells contribute to podocyte recovery in a model of acute proteinuria, Sci. Rep., 8, 10.1038/s41598-018-33082-x · DOI
  12. Cao, 2014, Transplantation of mesenchymal stem cells recruits trophic macrophages to induce pancreatic beta cell regeneration in diabetic mice, Int. J. Biochem. Cell Biol., 53, 372, 10.1016/j.biocel.2014.06.003 · DOI
  13. Linero, 2014, Paracrine effect of mesenchymal stem cells derived from human adipose tissue in bone regeneration, PLoS One, 9, 10.1371/journal.pone.0107001 · DOI
  14. Maacha, 2020, Paracrine mechanisms of mesenchymal stromal cells in angiogenesis, Stem Cell. Int., 2020, 4356359
  15. Atiya, 2020, Mesenchymal stem cells in the tumor microenvironment, Adv. Exp. Med. Biol., 1234, 31, 10.1007/978-3-030-37184-5_3 · DOI
  16. Cheng, 2021, LncRNA SNHG7 regulates mesenchymal stem cell through the notch1/Jagged1/Hes-1 signaling pathway and influences Folfirinox resistance in pancreatic cancer, Front. Oncol., 11, 719855, 10.3389/fonc.2021.719855 · DOI
  17. Shi, 2017, Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets, Nature reviews, Drug Discov., 16, 35, 10.1038/nrd.2016.193 · DOI
  18. He, 2018, Exosome theranostics: biology and translational medicine, Theranostics, 8, 237, 10.7150/thno.21945 · DOI
  19. Yang, 2020, Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics, Theranostics, 10, 3684, 10.7150/thno.41580 · DOI
  20. Milane, 2015, Exosome mediated communication within the tumor microenvironment, J. Contr. Release : Off. J. Control. Releas. Soc., 219, 278, 10.1016/j.jconrel.2015.06.029 · DOI
  21. Greening, 2015, Exosomes and their roles in immune regulation and cancer, Semin. Cell Dev. Biol., 40, 72, 10.1016/j.semcdb.2015.02.009 · DOI
  22. Forsberg, 2020, Mesenchymal stromal cells and exosomes: progress and challenges, Front. Cell Development. Biol., 8, 665, 10.3389/fcell.2020.00665 · DOI
  23. Mittelbrunn, 2011, Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells, Nat. Commun., 2, 282, 10.1038/ncomms1285 · DOI
  24. Lou, 2017, Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases, Exp. Mol. Med., 49, 10.1038/emm.2017.63 · DOI
  25. Xu, 2019, Exosomes derived from pro-inflammatory bone marrow-derived mesenchymal stem cells reduce inflammation and myocardial injury via mediating macrophage polarization, J. Cell Mol. Med., 23, 7617, 10.1111/jcmm.14635 · DOI
  26. Zheng, 2018, Mesenchymal stromal cell-derived extracellular vesicles: regenerative and immunomodulatory effects and potential applications in sepsis, Cell Tissue Res., 374, 1, 10.1007/s00441-018-2871-5 · DOI
  27. Yang, 2020, Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression, Signal Transduct. Targeted Ther., 5, 242, 10.1038/s41392-020-00359-5 · DOI
  28. Stremersch, 2016, Therapeutic and diagnostic applications of extracellular vesicles, J. Contr. Release, 244, 167, 10.1016/j.jconrel.2016.07.054 · DOI
  29. Colombo, 2014, Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles, Annu. Rev. Cell Dev. Biol., 30, 255, 10.1146/annurev-cellbio-101512-122326 · DOI · Paper page
  30. Grange, 2011, Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche, Cancer Res., 71, 5346, 10.1158/0008-5472.CAN-11-0241 · DOI
  31. Ratajczak, 2006, Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery, Leukemia, 20, 847, 10.1038/sj.leu.2404132 · DOI
  32. Tian, 2014, A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy, Biomaterials, 35, 2383, 10.1016/j.biomaterials.2013.11.083 · DOI
  33. Wei, 2020, Mesenchymal stem cell-derived exosomes: a promising biological tool in nanomedicine, Front. Pharmacol., 11, 590470, 10.3389/fphar.2020.590470 · DOI
  34. Zhao, 2016, Multifunctional transmembrane protein ligands for cell-specific targeting of plasma membrane-derived vesicles, Small, 12, 3837, 10.1002/smll.201600493 · DOI · Paper page
  35. Zhao, 2021, In situ activation of STING pathway with polymeric SN38 for cancer chemoimmunotherapy, Biomaterials, 268, 120542, 10.1016/j.biomaterials.2020.120542 · DOI
  36. Yu, 2014, Exosomes derived from mesenchymal stem cells, Int. J. Mol. Sci., 15, 4142, 10.3390/ijms15034142 · DOI
  37. Roccaro, 2013, BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression, J. Clin. Invest., 123, 1542, 10.1172/JCI66517 · DOI
  38. Fonsato, 2012, Human liver stem cell-derived microvesicles inhibit hepatoma growth in SCID mice by delivering antitumor microRNAs, Stem Cells (Dayton, Ohio), 30, 1985, 10.1002/stem.1161 · DOI
  39. Qin, 2020, Bone marrow-derived mesenchymal stem cell-derived exosomal microRNA-208a promotes osteosarcoma cell proliferation, migration, and invasion, J. Cell. Physiol., 235, 4734, 10.1002/jcp.29351 · DOI
  40. He, 2020, Human umbilical cord mesenchymal stem cells-derived exosomes deliver microRNA-375 to downregulate ENAH and thus retard esophageal squamous cell carcinoma progression, J. Exp. Clin. Cancer Res. : CR (Clim. Res.), 39, 140, 10.1186/s13046-020-01631-w · DOI
  41. Bolandi, 2020, Adipose derived mesenchymal stem cell exosomes loaded with miR-10a promote the differentiation of Th17 and Treg from naive CD4(+) T cell, Life Sci., 259, 10.1016/j.lfs.2020.118218 · DOI
  42. Gu, 2016, Exosomes derived from human mesenchymal stem cells promote gastric cancer cell growth and migration via the activation of the Akt pathway, Mol. Med. Rep., 14, 3452, 10.3892/mmr.2016.5625 · DOI
  43. Zhu, 2012, Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo, Cancer Lett., 315, 28, 10.1016/j.canlet.2011.10.002 · DOI · Paper page
  44. Wang, 2014, Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells, Blood, 124, 555, 10.1182/blood-2014-03-562439 · DOI
  45. Shi, 2016, Mesenchymal stem cell-derived exosomes facilitate nasopharyngeal carcinoma progression, Am. J. Canc. Res., 6, 459
  46. Wang, 2014, Deregulated microRNAs in gastric cancer tissue-derived mesenchymal stem cells: novel biomarkers and a mechanism for gastric cancer, Br. J. Cancer, 110, 1199, 10.1038/bjc.2014.14 · DOI
  47. Lin, 2013, Exosomes from human adipose-derived mesenchymal stem cells promote migration through Wnt signaling pathway in a breast cancer cell model, Mol. Cell. Biochem., 383, 13, 10.1007/s11010-013-1746-z · DOI
  48. Du, 2014, Microvesicles derived from human Wharton's jelly mesenchymal stem cells promote human renal cancer cell growth and aggressiveness through induction of hepatocyte growth factor, PLoS One, 9
  49. Del Fattore, 2015, Immunoregulatory effects of mesenchymal stem cell-derived extracellular vesicles on T lymphocytes, Cell Transplant., 24, 2615, 10.3727/096368915X687543 · DOI
  50. Ti, 2015, LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b, J. Transl. Med., 13, 308, 10.1186/s12967-015-0642-6 · DOI
  51. Zhu, 2014, Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice, Stem Cells (Dayton, Ohio), 32, 116, 10.1002/stem.1504 · DOI · Paper page
  52. Chen, 2016, Immunomodulatory effects of mesenchymal stromal cells-derived exosome, Immunol. Res., 64, 831, 10.1007/s12026-016-8798-6 · DOI · Paper page
  53. Amarnath, 2015, Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivo, Stem Cells (Dayton, Ohio), 33, 1200, 10.1002/stem.1934 · DOI
  54. Zhang, 2014, Mesenchymal stem cells secrete immunologically active exosomes, Stem Cell. Dev., 23, 1233, 10.1089/scd.2013.0479 · DOI
  55. Deuse, 2011, Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells, Cell Transplant., 20, 655, 10.3727/096368910X536473 · DOI
  56. Ren, 2019, Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via miR-21-5p delivery, J. Exp. Clin. Cancer Res. : CR (Clim. Res.), 38, 62, 10.1186/s13046-019-1027-0 · DOI
  57. Lopatina, 2014, Platelet-derived growth factor regulates the secretion of extracellular vesicles by adipose mesenchymal stem cells and enhances their angiogenic potential, Cell Commun. Signal. : CCS, 12, 26, 10.1186/1478-811X-12-26 · DOI
  58. Gong, 2017, Mesenchymal stem cells release exosomes that transfer miRNAs to endothelial cells and promote angiogenesis, Oncotarget, 8, 45200, 10.18632/oncotarget.16778 · DOI
  59. Zhu, 2021, Macrophage migration inhibitory factor facilitates the therapeutic efficacy of mesenchymal stem cells derived exosomes in acute myocardial infarction through upregulating miR-133a-3p, J. Nanobiotechnol., 19, 61, 10.1186/s12951-021-00808-5 · DOI
  60. Yu, 2020, Exosomes derived from atorvastatin-pretreated MSC accelerate diabetic wound repair by enhancing angiogenesis via AKT/eNOS pathway, Stem Cell Res. Ther., 11, 350, 10.1186/s13287-020-01824-2 · DOI
  61. Xu, 2019, Exosome-transmitted PSMA3 and PSMA3-AS1 promote proteasome inhibitor resistance in multiple myeloma, Clin. Cancer Res. : Off. J. Am. Assoc. Canc. Res., 25, 1923, 10.1158/1078-0432.CCR-18-2363 · DOI
  62. Ono, 2014, Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells, Sci. Signal., 7, ra63, 10.1126/scisignal.2005231 · DOI
  63. Lin, 2014, Bone marrow mesenchymal stem cell-derived microvesicles protect rat pheochromocytoma PC12 cells from glutamate-induced injury via a PI3K/Akt dependent pathway, Neurochem. Res., 39, 922, 10.1007/s11064-014-1288-0 · DOI
  64. Ji, 2015, Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer, Cell Cycle, 14, 2473, 10.1080/15384101.2015.1005530 · DOI
  65. Barbieri, 2008, Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas, Clin. Cancer Res. : Off. J. Am. Assoc. Canc. Res., 14, 5022, 10.1158/1078-0432.CCR-07-4717 · DOI
  66. Zeng, 2006, Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias, Mol. Cancer Therapeut., 5, 3113, 10.1158/1535-7163.MCT-06-0228 · DOI
  67. Bliss, 2016, Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow, Cancer Res., 76, 5832, 10.1158/0008-5472.CAN-16-1092 · DOI
  68. Yang, 2019, Tumor mesenchymal stromal cells regulate cell migration of atypical teratoid rhabdoid tumor through exosome-mediated miR155/SMARCA4 pathway, Cancers, 11, 10.7150/jca.28134 · DOI
  69. Biswas, 2019, Exosomes produced by mesenchymal stem cells drive differentiation of myeloid cells into immunosuppressive M2-polarized macrophages in breast cancer, J. Immunol., 203, 3447, 10.4049/jimmunol.1900692 · DOI
  70. Chen, 2021, G6PD-NF-κB-HGF signal in gastric cancer-associated mesenchymal stem cells promotes the proliferation and metastasis of gastric cancer cells by upregulating the expression of HK2, Front. Oncol., 11
  71. Raghavan, 2020, Carcinoma-associated mesenchymal stem cells promote chemoresistance in ovarian cancer stem cells via PDGF signaling, Cancers, 12, 10.3390/cancers12082063 · DOI
  72. Lin, 2016, Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities, Oncogene, 35, 6038, 10.1038/onc.2016.131 · DOI
  73. Kumar, 2018, Cancer-associated fibroblasts drive glycolysis in a targetable signaling loop implicated in Head and neck squamous cell carcinoma progression, Cancer Res., 78, 3769, 10.1158/0008-5472.CAN-17-1076 · DOI
  74. Dostert, 2017, How do mesenchymal stem cells influence or are influenced by microenvironment through extracellular vesicles communication?, Front. Cell Development. Biol., 5, 6, 10.3389/fcell.2017.00006 · DOI
  75. Yeon, 2018, Cancer-derived exosomes trigger endothelial to mesenchymal transition followed by the induction of cancer-associated fibroblasts, Acta Biomater., 76, 146, 10.1016/j.actbio.2018.07.001 · DOI
  76. Donnarumma, 2017, Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer, Oncotarget, 8, 19592, 10.18632/oncotarget.14752 · DOI
  77. Ham, 2021, Cancer-associated fibroblast-induced resistance to chemotherapy and radiotherapy in gastrointestinal cancers, Cancers, 13, 10.3390/cancers13051172 · DOI
  78. Gu, 2012, Gastric cancer exosomes trigger differentiation of umbilical cord derived mesenchymal stem cells to carcinoma-associated fibroblasts through TGF-β/Smad pathway, PLoS One, 7, 10.1371/journal.pone.0052465 · DOI
  79. Gu, 2021, The role of PKM2 nuclear translocation in the constant activation of the NF-κB signaling pathway in cancer-associated fibroblasts, Cell Death Dis., 12, 291, 10.1038/s41419-021-03579-x · DOI
  80. Li, 2019, Human umbilical cord mesenchymal stem cell-derived extracellular vesicles inhibit endometrial cancer cell proliferation and migration through delivery of exogenous miR-302a, Stem Cell. Int.
  81. Pakravan, 2017, MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1α/VEGF signaling axis in breast cancer cells, Cell. Oncol., 40, 457, 10.1007/s13402-017-0335-7 · DOI
  82. Zhang, 2020, Exosomes derived from human bone marrow mesenchymal stem cells transfer miR-222-3p to suppress acute myeloid leukemia cell proliferation by targeting IRF2/INPP4B, Mol. Cell. Probes, 51, 10.1016/j.mcp.2020.101513 · DOI
  83. Katakowski, 2013, Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth, Cancer Lett., 335, 201, 10.1016/j.canlet.2013.02.019 · DOI · Paper page
  84. Yao, 2021, Exosomal circ_0030167 derived from BM-MSCs inhibits the invasion, migration, proliferation and stemness of pancreatic cancer cells by sponging miR-338-5p and targeting the Wif1/Wnt8/β-catenin axis, Cancer Lett., 512, 38, 10.1016/j.canlet.2021.04.030 · DOI
  85. Zhou, 2013, Mesenchymal stromal cells augment CD4+ and CD8+ T-cell proliferation through a CCL2 pathway, Cytotherapy, 15, 1195, 10.1016/j.jcyt.2013.05.009 · DOI
  86. Li, 2021, Exosomes derived from mesenchymal stem cells curbs the progression of clear cell renal cell carcinoma through T-cell immune response, Cytotechnology, 73, 593, 10.1007/s10616-021-00480-5 · DOI
  87. Zhou, 2021, Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment, Biomaterials, 268, 10.1016/j.biomaterials.2020.120546 · DOI · Paper page
  88. Lee, 2013, Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells, PLoS One, 8, 10.1371/journal.pone.0084256 · DOI
  89. Rosenberger, 2019, Stem cell exosomes inhibit angiogenesis and tumor growth of oral squamous cell carcinoma, Sci. Rep., 9, 663, 10.1038/s41598-018-36855-6 · DOI
  90. Alcayaga-Miranda, 2016, Prostate tumor-induced angiogenesis is blocked by exosomes derived from menstrual stem cells through the inhibition of reactive oxygen species, Oncotarget, 7, 44462, 10.18632/oncotarget.9852 · DOI
  91. Wu, 2013, Microvesicles derived from human umbilical cord Wharton's jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo, PLoS One, 8
  92. Lou, 2020, MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway, J. Exp. Clin. Cancer Res. : CR (Clim. Res.), 39, 4, 10.1186/s13046-019-1512-5 · DOI
  93. Lou, 2015, Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma, J. Hematol. Oncol., 8, 122, 10.1186/s13045-015-0220-7 · DOI · Paper page
  94. Alvarez-Erviti, 2011, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes, Nat. Biotechnol., 29, 341, 10.1038/nbt.1807 · DOI · Paper page
  95. Shao, 2020, Advances in exosome-based drug delivery and tumor targeting: from tissue distribution to intracellular fate, Int. J. Nanomed., 15, 9355, 10.2147/IJN.S281890 · DOI · Paper page
  96. Wang, 2020, High-throughput single-cell analysis of exosome mediated dual drug delivery, in vivo fate and synergistic tumor therapy, Nanoscale, 12, 13742, 10.1039/D0NR02344B · DOI
  97. Tang, 2020, Extracellular vesicle-based Nanotherapeutics: emerging frontiers in anti-inflammatory therapy, Theranostics, 10, 8111, 10.7150/thno.47865 · DOI
  98. Melzer, 2019, Taxol-loaded MSC-derived exosomes provide a therapeutic vehicle to target metastatic breast cancer and other carcinoma cells, Cancers, 11, 10.3390/cancers11060798 · DOI
  99. Yeo, 2013, Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery, Adv. Drug Deliv. Rev., 65, 336, 10.1016/j.addr.2012.07.001 · DOI · Paper page
  100. Yang, 2018, Surface functionalization of polymeric nanoparticles with umbilical cord-derived mesenchymal stem cell membrane for tumor-targeted therapy, ACS Appl. Mater. Interfaces, 10, 22963, 10.1021/acsami.8b05363 · DOI
  101. Ankrum, 2014, Mesenchymal stem cells: immune evasive, not immune privileged, Nat. Biotechnol., 32, 252, 10.1038/nbt.2816 · DOI
  102. Jain, 2010, Delivering nanomedicine to solid tumors, Nat. Rev. Clin. Oncol., 7, 653, 10.1038/nrclinonc.2010.139 · DOI
  103. Haney, 2015, Exosomes as drug delivery vehicles for Parkinson's disease therapy, J. Contr. Release : Off. J. Control. Releas. Soc., 207, 18, 10.1016/j.jconrel.2015.03.033 · DOI · Paper page
  104. Kooijmans, 2013, Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles, J. Contr. Release : Off. J. Control. Releas. Soc., 172, 229, 10.1016/j.jconrel.2013.08.014 · DOI · Paper page
  105. Jafari, 2020, Designer exosomes: a new platform for biotechnology therapeutics, BioDrugs, 34, 567, 10.1007/s40259-020-00434-x · DOI
  106. Kim, 2016, Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells, Nanomed. Nanotechnol. Biol. Med., 12, 655, 10.1016/j.nano.2015.10.012 · DOI · Paper page
  107. Le Saux, 2020, Post-production modifications of murine mesenchymal stem cell (mMSC) derived extracellular vesicles (EVs) and impact on their cellular interaction, Biomaterials, 231, 10.1016/j.biomaterials.2019.119675 · DOI
  108. Bosch, 2016, Trehalose prevents aggregation of exosomes and cryodamage, Sci. Rep., 6, 10.1038/srep36162 · DOI
  109. Le Saux, 2021, Interest of extracellular vesicles in regards to lipid nanoparticle based systems for intracellular protein delivery, Adv. Drug Deliv. Rev., 10.1016/j.addr.2021.113837 · DOI
  110. Bagheri, 2020, Targeted doxorubicin-loaded mesenchymal stem cells-derived exosomes as a versatile platform for fighting against colorectal cancer, Life Sci., 261, 118369, 10.1016/j.lfs.2020.118369 · DOI
  111. Nitzsche, 2017, Concise review: MSC adhesion cascade-insights into homing and transendothelial migration, Stem Cells (Dayton, Ohio), 35, 1446, 10.1002/stem.2614 · DOI
  112. Wu, 2019, Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression, J. Hematol. Oncol., 12, 53, 10.1186/s13045-019-0739-0 · DOI
  113. Vidal, 2020, Exosomes and GPI-anchored proteins: Judicious pairs for investigating biomarkers from body fluids, Adv. Drug Deliv. Rev., 161–162, 110, 10.1016/j.addr.2020.08.006 · DOI
  114. Hung, 2015, Stabilization of exosome-targeting peptides via engineered glycosylation, J. Biol. Chem., 290, 8166, 10.1074/jbc.M114.621383 · DOI
  115. Salunkhe, 2020, Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: strategies and significance, J. Contr. Release : Off. J. Control. Releas. Soc., 326, 599, 10.1016/j.jconrel.2020.07.042 · DOI
  116. Tian, 2018, Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy, Biomaterials, 150, 137, 10.1016/j.biomaterials.2017.10.012 · DOI · Paper page
  117. Kooijmans, 2016, PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time, J. Contr. Release : Off. J. Control. Releas. Soc., 224, 77, 10.1016/j.jconrel.2016.01.009 · DOI
  118. Shen, 2018, Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies, Oncotarget, 9, 4485, 10.18632/oncotarget.23321 · DOI
  119. Yu, 2019, Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells, Cancer Sci., 110, 3173, 10.1111/cas.14181 · DOI
  120. Feng, 2021, Folic acid-modified Exosome-PH20 enhances the efficiency of therapy via modulation of the tumor microenvironment and directly inhibits tumor cell metastasis, Bioact. Mater., 6, 963
  121. Jiang, 2012, Effective targeting of the tumor microenvironment for cancer therapy, Anticancer Res., 32, 1203
  122. Stern, 2006, Hyaluronidases: their genomics, structures, and mechanisms of action, Chem. Rev., 106, 818, 10.1021/cr050247k · DOI
  123. Vogus, 2017, A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer, J. Contr. Release : Off. J. Control. Releas. Soc., 267, 191, 10.1016/j.jconrel.2017.08.016 · DOI
  124. Zhang, 2013, Multifunctional envelope-type mesoporous silica nanoparticles for tumor-triggered targeting drug delivery, J. Am. Chem. Soc., 135, 5068, 10.1021/ja312004m · DOI
  125. Piperigkou, 2021, Key matrix remodeling enzymes: functions and targeting in cancer, Cancers, 13
  126. Gomari, 2019, Targeted delivery of doxorubicin to HER2 positive tumor models, Int. J. Nanomed., 14, 5679, 10.2147/IJN.S210731 · DOI · Paper page
  127. Mendt, 2018, Generation and testing of clinical-grade exosomes for pancreatic cancer, JCI Insight, 3
  128. Xunian, 2020, Biology and therapeutic potential of mesenchymal stem cell-derived exosomes, Cancer Sci., 111, 3100, 10.1111/cas.14563 · DOI
  129. Jafarzadeh, 2019, Alteration of cellular and immune-related properties of bone marrow mesenchymal stem cells and macrophages by K562 chronic myeloid leukemia cell derived exosomes, J. Cell. Physiol., 234, 3697, 10.1002/jcp.27142 · DOI
  130. Wang, 2021, Human mesenchymal stem cell-derived exosomal microRNA-143 promotes apoptosis and suppresses cell growth in pancreatic cancer via target gene regulation, Front. Genet., 12, 581694, 10.3389/fgene.2021.581694 · DOI
  131. Gomari, 2018, Targeted cancer therapy using engineered exosome as a natural drug delivery vehicle, OncoTargets Ther., 11, 5753, 10.2147/OTT.S173110 · DOI

Cited by

Sorted by citations

Metadata

Authors
Zhang, F., Guo, J., Zhang, Z., Qian, Y., Wang, G., Duan, M., Zhao, H., Yang, Z., & Jiang, X.
Venue
Cancer Letters
Publisher
Elsevier BV
Published
2022-02
Volume
526
Pages
29-40
ISSN
0304-3835
DOI
10.1016/j.canlet.2021.11.015
Cited by
127
References
12
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review